Table 2 Participant characteristics in HIV cure trials
From: Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research
Study agents | RV411 | RV397 | RV409 | RV405 | |||
|---|---|---|---|---|---|---|---|
N/A | VRC01 | Placebo | VHM | Placebo | Ad26/MVA | Placebo | |
Number of participants | 8 | 13 | 5 | 10 | 5 | 17 | 9 |
Median age | 29 | 32 | 25 | 28 | 26 | 24 | 25 |
Male (%) | 87.5 | 100 | 100 | 89 | 75 | 100 | 100 |
Median HIV RNA pre-ART, log10 c/mL | 4.3 | 3.1 | 2.7 | 6.1 | 5.6 | 5.9 | 6.4 |
Median CD4, cells/mm3 pre-ART | 413 | 769 | 552 | 397 | 532 | 633 | 586 |
Median CD4/CD8 ratio pre-ART | 0.8 | 1.1 | 0.9 | 0.4 | 0.8 | 0.6 | 0.6 |
Median duration of ART (years) | 2.8 | 3.1 | 2.7 | 4.3 | 3.0 | 2.2 | 2.2 |
Fiebig stage (number) | I: 8 | I/II: 8 III: 5 | I/II: 3 III: 2 | III: 8 IV: 2 | III: 5 | I: 0 II: 6 III: 6 IV: 5 | I: 1 II: 4 III: 4 IV: 0 |